Sono-Tek Corporation (Nasdaq: SOTK) — FY2022 Form 10-K
Reporting period: Fiscal year ended February 28, 2022, compared with the year ended February 28, 2021. This is an annual filing, not a standalone 2021 fourth-quarter report.
Business context
Sono-Tek designs and manufactures custom ultrasonic coating systems used in electronics and microelectronics, medical devices, alternative energy, industrial applications, and research and development. It reported record annual sales and attributed growth to demand for complete, higher-value systems, including multi-axis equipment. Approximately 68% of FY2022 sales came from outside the United States and Canada.
Key financial results
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| Net sales | $17.13 million | $14.83 million | +16% |
| Gross profit / margin | $8.61 million / 50.3% | $7.00 million / 47.2% | Margin +3.1 percentage points |
| Operating income / margin | $1.89 million / 11% | $1.34 million / 9% | Operating income +41% |
| Net income | $2.54 million | $1.12 million | +127% |
| Basic and diluted EPS | $0.16 | $0.07 | +$0.09 |
| Cash from operating activities | $2.32 million | $0.73 million | +$1.59 million |
Gross-margin improvement reflected stronger sales, favorable product mix, operating efficiencies, and lower-than-expected warranty and installation costs. Net income included a $1.005 million gain from forgiveness of the Paycheck Protection Program (PPP) loan; therefore, reported earnings growth was partly attributable to this nonrecurring item. Operating expenses rose 19% to $6.72 million, including higher selling costs, commissions, professional fees, and stock-based compensation. Research and development spending was $1.73 million, or 10.1% of sales.
Liquidity, debt, and cash flow
At February 28, 2022, cash and cash equivalents were $4.84 million and marketable securities were $5.87 million, totaling $10.71 million, up from $8.65 million a year earlier. Working capital increased to $10.78 million from $8.90 million. The company reported no outstanding borrowings under its $1.5 million revolving credit line and no long-term debt at year-end; $5,000 of the facility supported a letter of credit. The prior-year balance included the $1.002 million PPP loan, forgiven during FY2022.
Operating activities provided $2.32 million; investing activities used $1.63 million, primarily reflecting $1.30 million of net purchases of marketable securities and $327,000 of capital spending; financing activities provided $69,000, principally from stock-option exercises. The filing highlights cash, cash equivalents, and short-term investments as $10.71 million; cash and cash equivalents alone increased by $756,000.
Material changes and operating trends
- Multi-Axis Coating Systems sales increased 77% to $9.91 million, or 58% of revenue. OEM Systems sales rose 51% to $2.38 million.
- Integrated Coating Systems sales fell 72% to $1.18 million, largely because a large textile-system order shipped in FY2021 did not recur.
- By market, alternative energy rose 72% to $3.69 million, medical rose 29% to $4.34 million, and electronics/microelectronics rose 19% to $7.13 million. Industrial sales declined 53% to $1.06 million, partly reflecting the prior-year textile order.
- Backlog was $5.3 million at year-end, up 38% from $3.8 million. Two customers represented 24% of FY2022 sales; three customers represented 41% of year-end receivables.
- The company’s common stock began trading on Nasdaq Capital Market in August 2021, moving from its prior OTCQX platform.
Outlook, risks, and unusual items
The filing provides no specific numerical revenue or earnings guidance. Management cited the year-end backlog and expansion into clean energy, medical, and semiconductor applications as growth supports. It also warned that supply-chain constraints, especially electronic-component shortages and extended lead times, could continue through FY2023. Management expected travel and trade-show spending to rise as activities resumed, while inflation, higher labor and shipping costs, geopolitical uncertainty, and COVID-19 remained risks.
Other significant risks include dependence on individual purchase orders and a concentrated customer base, substantial international sales exposure, reliance on a single manufacturing site in Milton, New York, and potential constraints on manufacturing capacity. The company reported no material commitments or contingencies other than a letter of credit, and no off-balance-sheet arrangements. It reported effective disclosure controls and effective management-assessed internal control over financial reporting; the auditor did not express an opinion on internal-control effectiveness. The financial-statement audit opinion was unqualified.
Filing detail to reconcile: The MD&A says PPP forgiveness was approved April 1, 2021, while the debt note states notice was received in April 2022. The financial statements record the $1.005 million forgiveness gain in FY2022. The filing text does not clearly reconcile these dates.
Most important facts for investors to verify
- How much of the 127% net-income increase reflects ongoing operations versus the $1.005 million PPP forgiveness gain.
- Whether the $5.3 million backlog converts to revenue on schedule, and how concentrated the related orders and receivables remain.
- Whether component shortages, longer lead times, inflation, and labor costs affect production capacity, delivery schedules, and margins.
- Whether growth in multi-axis systems and clean-energy, medical, and semiconductor applications can offset declines or lumpy large orders in other product lines.
- The timing inconsistency in the PPP forgiveness disclosure and the resulting FY2022 accounting treatment.